Cabozanix 20 mg

This comparison gets at something genuinely interesting in targeted oncology drug design — both drugs are multikinase inhibitors that block VEGFR, but their differences in target breadth, specific kinase coverage, and the biological problems they were engineered to solve reflect different generations of thinking about what makes anti-angiogenic therapy fail.

The shared foundation — both block VEGFR to cut off tumor blood supply

As we discussed when covering sorafenib earlier in this conversation, the core anti-angiogenic strategy common to both drugs involves blocking VEGFR (vascular endothelial growth factor receptor) on the cells lining tumor blood vessels, preventing the cancer from recruiting the new blood supply it needs to grow beyond a small size. This VEGFR-blocking approach is the foundational mechanism shared across the entire class of anti-angiogenic multikinase inhibitors.

Both drugs also inhibit tumor cell proliferation through additional kinase targets beyond VEGFR — so both are working through a combination of anti-angiogenic starvation and direct anti-proliferative effects simultaneously, rather than relying on a single mechanism.

Sorafenib’s target profile — RAF/VEGFR/PDGFR

As we covered in the Sonib page, sorafenib’s key targets are RAF kinases (including CRAF and BRAF, blocking the RAS-RAF-MEK-ERK growth signaling pathway directly inside cancer cells), VEGFR (anti-angiogenic), and PDGFR (supporting blood vessel maturation). This combination was specifically designed for cancers like HCC and RCC that lack a single dominant, cleanly druggable mutation but depend heavily on this network of growth and vascular signaling.

Cabozantinib’s target profile — broader, with MET and AXL as the defining additions

In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. This is a substantially broader target list than sorafenib, but the two additions that matter most clinically are MET and AXL — and understanding why requires understanding how cancer cells escape from anti-VEGFR therapy.

Why MET inhibition is the most important distinguishing feature

MET (also called hepatocyte growth factor receptor, or HGFR) is a receptor tyrosine kinase that, when activated by its ligand HGF, triggers cell growth, survival, migration, and invasion. MET is directly relevant to anti-VEGFR resistance because when tumors are treated with VEGFR-blocking drugs like sorafenib, they frequently respond by upregulating MET signaling as an alternative pathway to sustain growth and stimulate new blood vessel formation through a VEGFR-independent route. This MET-driven escape from anti-VEGFR therapy is one of the most well-characterized resistance mechanisms in HCC and RCC specifically.

By simultaneously blocking both VEGFR and MET, cabozantinib cuts off both the primary anti-angiogenic target and this most common escape pathway at the same time — directly addressing the resistance mechanism that sorafenib cannot block and that typically limits sorafenib’s durability of response. This is mechanistically why cabozantinib retains activity in post-sorafenib HCC, as we discussed in the comparison page: it blocks MET-driven growth signals that sorafenib left fully available.

Why AXL inhibition adds a further dimension

AXL (GAS6 receptor) is a tyrosine kinase implicated in the development of resistance to RCC therapy. AXL activation has been associated with resistance to multiple targeted therapies across several cancer types — it promotes cancer cell survival, epithelial-to-mesenchymal transition (a process that makes cancer cells more invasive and prone to metastasis), and immune evasion. By blocking AXL alongside VEGFR and MET, cabozantinib addresses a third resistance-associated escape pathway that neither sorafenib nor most other anti-VEGFR agents touch.

RET inhibition — why this matters for medullary thyroid cancer specifically

RET is a receptor tyrosine kinase whose mutations or rearrangements are the most common driver of medullary thyroid cancer — almost all hereditary medullary thyroid cancers, and a substantial proportion of sporadic cases, are driven by activating RET mutations. Sorafenib has some RET inhibitory activity but it’s not particularly potent against this target. Cabozantinib’s more potent RET inhibition is a central reason why it has meaningful activity specifically in medullary thyroid cancer, providing direct anti-tumor activity against the primary driver mutation rather than relying purely on the anti-angiogenic mechanism.

How the mechanism explains the different clinical niches

This target profile difference directly explains the clinical positioning we discussed in the HCC comparison:

Sorafenib’s RAF/VEGFR/PDGFR coverage was effective enough to establish first-line activity in HCC and RCC, but its lack of MET and AXL coverage means that as tumors develop resistance through these alternative pathways, sorafenib has no further activity.

Cabozantinib’s additional MET and AXL coverage means it can continue to block tumor growth even after sorafenib-resistance mechanisms have been activated — which is precisely why it was developed and positioned as a post-sorafenib option rather than a simple alternative in the same first-line setting.

Why broader isn’t simply “better” — the tolerability trade-off

This is worth being clear about: cabozantinib’s broader kinase inhibition doesn’t make it unconditionally superior to sorafenib. Each additional kinase target that’s blocked is also a normal cellular function being disrupted somewhere in the body. Cabozantinib’s broader target coverage contributes to its distinctive safety profile — the GI perforation and fistula risk (related partly to broader vascular effects), the jaw osteonecrosis risk, and the particularly prominent hepatotoxicity in HCC patients all reflect the broader biological footprint of blocking more kinase pathways simultaneously. Sorafenib’s narrower targeting means its side-effect profile, while certainly significant (hand-foot skin reaction, hypertension, bleeding), is in some respects more predictable and more specifically mechanistically linked to its three primary targets.

The terminal half-life difference — a pharmacokinetic distinction

The predicted terminal half-life of cabozantinib is approximately 99 hours — roughly four days. This is substantially longer than sorafenib’s half-life of approximately 25-48 hours. The practical implication is that cabozantinib accumulates to steady-state more slowly and, importantly, takes longer to clear from the body when stopped. This long half-life is part of why the 28-day surgical stop requirement exists — cabozantinib’s prolonged presence in tissues means its anti-angiogenic effects (which impair wound healing) persist for longer after the last dose than a shorter half-life drug would.

The bigger picture

Cabozantinib represents a deliberate next step in anti-angiogenic kinase inhibitor design — not simply a more potent version of sorafenib’s same mechanism, but a purposeful broadening of target coverage to include the most common and most clinically important resistance pathways (MET and AXL) that limit the durability of first-generation VEGFR-blocking approaches. The result is a drug with genuine activity in settings where sorafenib has already failed, at the cost of a broader and in some respects more complex safety profile reflecting its wider biological footprint. Understanding this difference is exactly why these two drugs are positioned sequentially rather than as interchangeable alternatives — each was designed to address a distinct moment in the disease’s trajectory.